Failure to Implement MRR Recommendation and Monitor Anticoagulant Therapy
Summary
The facility failed to address and implement the Consulting Pharmacist’s recommendation from the monthly Medication Regimen Review for a resident with paranoid schizophrenia who was receiving Ativan 1 mg three times daily for anxiety. The physician’s order directed staff to monitor episodes of anxiety as exhibited by restlessness every shift, and the care plan included monitoring and recording target behavior occurrences. During the October 2025 MRR, the CP noted that “restlessness” was vague and subjective and asked that it be changed or corrected, but there was no documented evidence that the recommendation was addressed or acted on. Facility nurses and the DON stated that the behavior was too vague and should have been made more specific for staff monitoring, and the DON acknowledged that the recommendation was not followed through. The facility also failed to monitor a resident receiving rivaroxaban for signs and symptoms of bleeding or bruising for five months. The resident had diagnoses including hemiplegia and hemiparesis following a stroke and had a physician’s order for rivaroxaban for stroke prevention. Review of the clinical record showed no physician’s order and no documentation of monitoring for bleeding or bruising from the start of therapy through mid-December 2025. A nurse confirmed that the resident had been receiving rivaroxaban during that entire period and that there was no documentation of monitoring until the order appeared later. The nurse stated the resident should have been monitored for bruising and bleeding for safety because the resident was unable to express symptoms. The CP stated that the anticoagulant therapy should have been reviewed monthly for discrepancies and that the lack of monitoring for untoward side effects should have been captured during the MRR, but it was not. The DON stated the expectation was for nurses to monitor residents on anticoagulants for bleeding and bruising. Facility policy required monthly pharmacist review of each resident’s medication regimen to identify clinically significant risks or adverse consequences, and the anticoagulant policy stated that residents are monitored for bleeding and that anticoagulant therapy is reviewed monthly by the consultant pharmacist with follow-up documented as appropriate.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.